Search results for "Modality"

showing 10 items of 651 documents

Liver Transplantation for Hepatocellular Carcinoma After Yttrium Therapy: A Case Report

2008

Yttrium-90 microspheres constitute one of the most recent treatment options for hepatocellular carcinoma (HCC) in the setting of cirrhosis. As such, their spectrum of indication is not yet fully established. Herein, we have reported the case of a patient with HCC beyond the listing criteria for liver transplantation (OLT) who was treated preoperatively with selective transarterial chemoembolization and yttrium-90 microspheres. He was subsequently transplanted with a liver from an 81-year-old donor allocated through Eurotransplant as a "rescue offer." The posttransplant course was uneventful. Pathologic examination revealed a multifocal, well-differentiated pT2 tumor with no vascular invasio…

Malemedicine.medical_specialtyCarcinoma HepatocellularTime FactorsCirrhosismedicine.medical_treatmentLiver transplantationMicrospheremedicineHumansYttrium RadioisotopesChemoembolization TherapeuticAged 80 and overTransplantationbusiness.industryLiver NeoplasmsCancerTreatment optionsMiddle Agedmedicine.diseaseCombined Modality TherapyLiver TransplantationTumor recurrenceSurgeryTreatment Outcomesurgical procedures operativeHepatocellular carcinomaSurgerybusinessLiver cancerTransplantation Proceedings
researchProduct

Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia

2011

We conducted an international phase 2 trial to evaluate 2 dose levels of ofatumumab, a human CD20 mAb, combined with fludarabine and cyclophosphamide (O-FC) as frontline therapy for chronic lymphocytic leukemia (CLL). Patients with active CLL were randomized to ofatumumab 500 mg (n = 31) or 1000 mg (n = 30) day 1, with fludarabine 25 mg/m2 and cyclophosphamide 250 mg/m2 days 2-4, course 1; days 1-3, courses 2-6; every 4 weeks for 6 courses. The first ofatumumab dose was 300 mg for both cohorts. The median age was 56 years; 13% of patients had a 17p deletion; 64% had β2-microglobulin > 3.5 mg/L. Based on the 1996 National Cancer Institute Working Group (NCI-WG) guidelines, the complete respo…

Malemedicine.medical_specialtyCyclophosphamideClinical Trials and ObservationsChronic lymphocytic leukemiaImmunologyMedizinNeutropeniaOfatumumabAntibodies Monoclonal HumanizedBiochemistryGastroenterologychemistry.chemical_compoundChemoimmunotherapyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideCD20Chlorambucilbiologybusiness.industryAntibodies MonoclonalCell BiologyHematologyMiddle Agedmedicine.diseaseCombined Modality TherapyLeukemia Lymphocytic Chronic B-CellNeoadjuvant TherapySurgeryFludarabineTreatment Outcomechemistrybiology.proteinFemaleImmunotherapybusinessVidarabinemedicine.drug
researchProduct

The treatment of venous leg ulcers: a new therapeutic use of iloprost

2007

Background: We conducted a study using an intravenous (i.v.) infusion of iloprost in the treatment of venous ulcers to verify whether the association of i.v. iloprost + local therapy + elastic compression has a favorable effect when compared with traditional treatment with local therapy and elastic compression. Study Design: We evaluated the effects of iloprost in 98 consecutive patients with noncomplicated venous ulcers of lower limbs subdivided into 2 groups: the first group (48 patients) received iloprost in saline solution for 3 weeks and the second group (50 patients) received a venous infusion of a saline solution. The patients were examined at baseline time 0 (first visit) and then a…

Malemedicine.medical_specialtyElastic compressionmedicine.medical_treatmentIschemiaPlacebo groupDrug Administration Schedulelaw.inventionRandomized controlled triallawmedicineHumansSingle-Blind MethodIloprostInfusions IntravenousVeinSalineDose-Response Relationship Drugbusiness.industryvenous ulcersiloprostLeg UlcerSignificant differenceMiddle Agedmedicine.diseaseCombined Modality TherapySurgeryTreatment Outcomemedicine.anatomical_structureDebridementAnesthesiaAnti-Infective Agents LocalFemaleSurgeryVENOUS LEG ULCERS ILOPROSTbusinessPlatelet Aggregation InhibitorsStockings CompressionIloprostmedicine.drug
researchProduct

Gastrointestinal stromal tumour of the rectum: Report of a case and review of literature

2008

Gastrointestinal stromal tumour (GIST) is a rare tumour of the gastrointestinal tract which does not generally originate in the rectum. The authors describe a case of a 70-year-old man who underwent an anterior resection of the rectum for a low-risk GIST. The patient was not given adjuvant chemotherapy with imatinib and is still disease-free 30 mo after surgery. The authors conclude that although rectal GIST is extremely uncommon, it should be included in differential diagnosis when a tumour in the rectum is detected. Biopsy of the tumour is essential, since this makes it possible to reach a sure preoperative diagnosis based on the immunohistological features of the CD117 and CD34. Although…

Malemedicine.medical_specialtyGastrointestinal Stromal TumorsCD34RectumAntigens CD34Antineoplastic AgentsCase ReportPiperazinesGIST;BiopsymedicineHumansneoplasmsAgedGastrointestinal tractGiSTmedicine.diagnostic_testbiologyRectal NeoplasmsCD117business.industryGastroenterologyGeneral MedicineCombined Modality Therapydigestive system diseasesSurgeryProto-Oncogene Proteins c-kitPyrimidinesTreatment Outcomemedicine.anatomical_structureImatinib mesylateBenzamidesImatinib Mesylatebiology.proteinDifferential diagnosisbusinessGISTWorld Journal of Gastroenterology
researchProduct

Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study

2014

The outcome of high-risk (HR) Acute Lymphoblastic Leukemia (ALL) patients enrolled in AIEOP-BFM ALL 2000 study (NCT00613457) in Italy is described. Overall, 1999 Philadelphia negative ALL patients entered the study. HR criteria were: minimal residual disease (MRD) levels ≥10-3 at day 78 (HR-MRD), no complete remission (no-CR) at day 33, t(4;11) translocation, Prednisone Poor Response (PPR). Treatment (2 years) included protocol I, 3 polychemotherapy blocks, delayed intensification (protocol IIx2 or IIIx3), cranial radiotherapy, maintenance. 312 HR patients (15.6% of the total) had 5-year event-free survival (EFS) and overall survival (OS) of 58.9%(SE 2.8) and 68.9%(2.6). In hierarchical ord…

Malemedicine.medical_specialtyNeoplasm ResidualAdolescentmedicine.medical_treatmentImmunologyChromosomal translocationhigh riskacute lymphoblastic leukemiaHematopoietic stem cell transplantationBiochemistryGastroenterologyAdolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child Preschool; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Neoplasm Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy; Remission Induction; Treatment Outcome; Hematology; Biochemistry; Cell Biology; ImmunologyPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy Protocolshigh risk; acute lymphoblastic leukemiaHumansMedicineNeoplasmPreschoolChildChemotherapyAntineoplastic Combined Chemotherapy ProtocolRadiotherapybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationInfantCell BiologyHematologyPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseCombined Modality TherapyMinimal residual diseaseSurgeryClinical trialRadiation therapyTreatment OutcomeN/ASettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAResidualChild PreschoolNeoplasmFemalebusinessHumanmedicine.drugBlood
researchProduct

Motor intracortical inhibition in PD: L-DOPA modulation of high-frequency rTMS effects

2007

Dopaminergic drugs and deep brain stimulation restore cortical inhibition in Parkinson disease (PD) patients. High-frequency rTMS was also found to increase cortical inhibition in PD but its therapeutic effect is still controversial. Here we hypothesize that, if dopaminergic drugs reverse to normal cortical excitability in M1, the effect of high-frequency (hf)-rTMS in PD patients could depend on whether they are in a medicated or unmedicated state. The present study aims to explore the lasting effects of sub-threshold hf rTMS trains over M1 on cortical inhibition in patients with "on" and without "off" L-DOPA treatment. Fourteen PD patients were examined twice while "on" and "off" medicatio…

Malemedicine.medical_specialtyNeurologyDeep brain stimulationCORTICAL SILENT PERIODmedicine.medical_treatmentStimulationMotor ActivityInhibitory postsynaptic potentialPAIRED-PULSE INHIBITIONAntiparkinson AgentsLevodopaDegenerative diseaseEVOKED-POTENTIALSmedicineHumansCORTEX EXCITABILITYAgedAged 80 and overSUBTHALAMIC NUCLEUSPARKINSONS-DISEASE PATIENTSGeneral NeuroscienceDopaminergicMotor CortexNeural InhibitionParkinson DiseaseMiddle Agedmedicine.diseaseFACILITATIONCombined Modality TherapyTranscranial Magnetic StimulationTranscranial magnetic stimulationBRAIN-STIMULATIONmedicine.anatomical_structureSettore MED/26 - NeurologiaFemaleREPETITIVE TMSPsychologyNeuroscienceMotor cortexExperimental Brain Research
researchProduct

Real-time ultrasonography in the otolaryngology office setting

1993

Over the past two decades, diagnostic ultrasonography has evolved into an extensively used noninvasive imaging modality. It plays a vital role in the disciplines of vascular surgery, cardiology, neonatology, pediatrics, ophthalmology, gynecology, and urology, to name a few, but it is in the field of obstetrics that this technology has been maximally used as an office procedure to evaluate the status of the fetus. In the evaluation of head and neck disorders, ultrasonography has been the subject of sporadic reports for the past 15 years.le3 However, except for the evaluation of thyroid masses,4 it has never been widely accepted in the United States as a diagnostic modality, and has taken a b…

Malemedicine.medical_specialtyNoninvasive imagingTime FactorsModality (human–computer interaction)medicine.diagnostic_testbusiness.industryMEDLINEMagnetic resonance imagingVascular surgeryPhysicians' OfficesSurgeryOtolaryngologyOtorhinolaryngologyOtorhinolaryngologyNeoplasmsmedicineHumansFemaleMedical physicsReal time ultrasonographyHead and neckbusinessUltrasonographyAmerican Journal of Otolaryngology
researchProduct

Individualized Comprehensive Lifestyle Intervention in Patients Undergoing Chemotherapy with Curative or Palliative Intent: Who Participates?

2015

Objective Knowledge about determinants of participation in lifestyle interventions in cancer patients undergoing chemotherapy, particularly with palliative intent, remains poor. The objective of the present study was to identify determinants of participating in a 12 month individualized, comprehensive lifestyle intervention, focusing on diet, physical activity, mental stress and smoking cessation, in cancer patients receiving chemotherapy with curative or palliative intent. The secondary objective was to identify participation determinants 4 months into the study. Methods Newly diagnosed cancer patients starting chemotherapy at the cancer center in Kristiansand/Norway (during a 16 month inc…

Malemedicine.medical_specialtyPalliative caremedicine.medical_treatmentlcsh:MedicineAntineoplastic AgentsBreast NeoplasmsBreast cancerInternal medicinemedicineHumansPrecision Medicinelcsh:ScienceLife StyleSocioeconomic statusAgedChemotherapyMultidisciplinarybusiness.industryPalliative Carelcsh:RProstatic NeoplasmsCancerMiddle Agedmedicine.diseaseCombined Modality TherapyPhysical therapySmoking cessationMarital statusFemaleSmoking Cessationlcsh:QColorectal NeoplasmsbusinessBody mass indexResearch ArticlePLOS ONE
researchProduct

Chemoradioimmunotherapy with 5-fluorouracil, cisplatin and interferon-α in pancreatic and periampullary cancer: Results of a feasibility study

2008

Abstract Background Recent studies give rise to the hypothesis, that adjuvant chemoradioimmunotherapy with 5-fluorouracil (5-FU), cisplatin and interferon-α (IFN-α) might be a possible new treatment of pancreatic cancer in resected patients. We report the up-to-now experience at our institution. Patients and methods Eleven patients with histological diagnosis of localized carcinoma of the pancreas ( n  = 7) or periampullary ( n  = 4) were prospectively analyzed. Four patients were deemed unresectable because of local invasion of adjacent organs (neoadjuvant setting) and seven patients underwent curative resection (adjuvant setting). Eight patients were classified as T3 carcinomas and three …

Malemedicine.medical_specialtyPancreatic diseasemedicine.medical_treatmentAntineoplastic AgentsRisk AssessmentGastroenterology03 medical and health sciences0302 clinical medicineInternal medicinePancreatic cancermedicinePeriampullary cancerHumansNeoplasm InvasivenessRadiology Nuclear Medicine and imagingSurvival rateNeoplasm Staging030304 developmental biology0303 health sciencesbusiness.industryPatient SelectionRadiotherapy Dosagemedicine.diseaseCombined Modality Therapypeople.cause_of_deathRecombinant Proteins3. Good healthSurgeryPancreatic NeoplasmsSurvival RateRadiation therapyOncology030220 oncology & carcinogenesisConcomitantInterferon Type IFeasibility StudiesFemaleFluorouracilImmunotherapyCisplatinbusinesspeopleChemoradiotherapyProgressive diseaseCancer/Radiothérapie
researchProduct

Linfomas malignos primários nas glandulas salivares

2011

Primary malignant lymphomas in the salivary glands are relatively rare. Clinical presentation is not characteristic and the disease is often overlooked resulting in diagnosis and treatment delays. AIM: To stress the importance of the diagnostic process and combined management, we present a series of eight patients with malignant lymphoma of the parotid who were diagnosed only after surgery and managed with radiation and chemotherapy. METHODS: Retrospective series of patients with primary malignant lymphoma of the parotid gland managed with radiotherapy and diagnostic surgical partial resection. RESULTS: After treatment completion we achieved a loco-regional control rate of 87.5%. Toxicity w…

Malemedicine.medical_specialtyPathologyglândulas salivaresSettore MED/06 - Oncologia Medicamedicine.medical_treatmentsalivary glandsSettore MED/19 - Chirurgia PlasticalymphomaDiseaseradioterapiaSettore MED/29 - Chirurgia Maxillofaccialestomatognathic systemlymphoma parotid salivary gland non-Hodgkin surgeryHumansMedicineStage (cooking)linfomalinfoma não hodgkinradiotherapyneoplasias parotídeasAgedRetrospective StudiesAged 80 and overPharmacologyChemotherapybusiness.industryLymphoma Non-HodgkinRate controlMiddle AgedPartial resectionmedicine.diseaseCombined Modality Therapynon-hodgkinLymphomaParotid glandRadiation therapyparotid neoplasmsTreatment Outcomemedicine.anatomical_structureSettore MED/31 - OtorinolaringoiatriaFemaleRadiologybusiness
researchProduct